Prof. Ronit Satchi-Fainaro (Ph.D.) is a Full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of Tel Aviv University and its 17-affiliated hospitals’ Cancer Biology Research Center, Director of the TAU Kahn 3D BioPrinting Initiative, and holds the Lion Chair in Nanosciences and Nanotechnologies. She serves on the BoD of Teva Pharmaceutical Industries Ltd. and the BoG of TAU, and is a member of the SAB of several Innovation Centers, Universities, Hospitals, Pharma and Biotech companies, Fellowship Committees, VCs, and editorial boards of scientific journals. The overarching goal of Prof. Satchi-Fainaro’s multidisciplinary research is to establish preclinical models of cancer in order to develop novel clinically-translatable nanomedicines targeting tumor cells and their microenvironment. Her interest in targeting the tumor stroma was initiated when she developed the first selective polymeric nanomedicines bearing angiogenesis inhibitors (Nature Medicine 2004; Cancer Cell 2005). The understanding that targeting only a single cellular compartment is not sufficient to foster a significant antitumor response, motivated her to focus on the development of combination nanomedicines that target tumor and host compartments synergistically (Angew Chem 2009). This new treatment modality has demonstrated great promise in multiple tumor types, with enhanced antitumor activity and reduced toxicity (eLife 2017; Nature Communications 2018). The design of novel efficacious anticancer therapies requires a better understanding of the complex molecular mechanisms underlying tumor development (Nature Communications 2021). Her European Research Council (ERC) grants (Consolidator, Advanced and PoC), which focus on studying molecular and cellular tumor-host interactions, have led to seminal discoveries that were the basis for the development of novel anticancer combination therapies remarkably prolonging tumor dormancy periods based on dormancy-associated molecular signatures (ACS Nano 2016, FASEB J 2018). Her research is focused on finding the key players involved in tumor-host interactions and designing nanomedicines that are activated by these players, including overexpressed enzymes such as cathepsins, or overproduced analytes such as H2O2. In one of her latest works, a combination of immunotherapy with nano-vaccines and ibrutinib led to tumour remission and prolonged survival in melanoma-bearing mice (Nature Nanotechnology 2019). Recently, she converted the same nano-vaccine platform to activate DC with SARS-CoV-2 peptides and RNAi against COVID-19 (Nature Nanotechnology 2020). This work was selected for funding out of hundreds of proposals to be awarded by The Israeli Innovation Authority together with Merck and by the Fundacion La Caixa. The nanomedicines she designs can be exploited for therapeutics, diagnostics, and image-guided-surgery while delivering diverse entities. These novel therapeutics as well as existing ones are tested on the lab’s unique 3D-bioprinted cancer models that mimic the clinical setting and is exploited for target discovery, drug development and personalized therapy (Science Advances 2021).She has published more than 150 manuscripts, 13 book chapters, edited two books, is named inventor on 60 patents, some of which were licensed to Pharmaceutical and Biotech companies. She founded three spin-off companies and is actively engaged in translational research with several industry partners and in science outreach.